Day: November 22, 2022

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

Written by Customer Service on November 22, 2022. Posted in Public Companies.

Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million The sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss moratorium proceedings Sale proceeds expected to position ObsEva to satisfy Nasdaq stockholders’ equity requirement for continued public listing ObsEva expects to have greater than one year of cash runway, providing strategic optionalityAd hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – November 22, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical company developing novel therapies for women’s health, today announced the sale of all of the Company’s rights to Ebopiprant to XOMA...

Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

Written by Customer Service on November 22, 2022. Posted in Public Companies.

Method–of–use–patent covers KIN001 in ophthalmic diseases Further strengthens already granted KIN001 US composition of matter patentBasel, Switzerland, 22 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases “ covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD). The method of use patent is on top of granted US Patent No. 11285155 that protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037. The...

argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

Written by Customer Service on November 22, 2022. Posted in Public Companies.

– Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 – Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod compared to intravenous (IV) administration November 22, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for SC efgartigimod (1000mg efgartigimod-PH20) for the treatment of adult patients with generalized myasthenia gravis (gMG). The application has been granted a Prescription Drug User Fee Act (PDUFA) target...

Unaudited financial results of Nordic Fibreboard AS for the third quarter of 2022

Written by Customer Service on November 22, 2022. Posted in Earnings Releases And Operating Results.

MANAGEMENT REPORT Consolidated net sales for Q3 2022 were € 2.79 million (Q3 2021: € 2.33 million). The main business area is the production and wholesale of fibreboard, which recorded sales in Q3 2022 of € 2.78 million, an increase of 23% compared to Q3 2021. The remaining business area is real estate management of the property owned in Suur-Jõe street in Pärnu, who recorded sales of € 9 thousand in Q3 2022 (Q3 2021: 65 thousand). The reason for the increase in sales revenue in Q3 2022 for Nordic Fibreboard Ltd was the ongoing strong demand for building materials in the construction sector, as reflected in both volume growth and price increases. That being said, towards the end of Q3 2022 we started to see a reduction in customers orders, reflecting the softening of business confidence as a result of negative macro factors, such as increasing...

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

Written by Customer Service on November 22, 2022. Posted in Public Companies.

SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the supplemental application for additional indications of adalimumab injection (project code: UBP1211, trade name: 君邁康®) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children has been approved by the National Medical Products Administration (“NMPA”). Tumor necrosis factor-α (TNF-α) is secreted by macrophages, mast cells and activated Th cells. It is a potent inducer of inflammatory response and a key regulator of innate immunity, playing a key...

Ads on Streaming Platforms Capture More Attention Than Ads on Social Media in India, According to New Magnite Research

Written by Customer Service on November 22, 2022. Posted in Public Companies.

64% of streamers in India report that they are more receptive to ads on streaming platforms than ads on social media MUMBAI, India, Nov. 22, 2022 (GLOBE NEWSWIRE) — Magnite (Nasdaq: MGNI), the world’s largest independent omnichannel sell-side advertising platform, today released a study entitled “India Embraces the Streaming Era” that found ads on streaming platforms capture more attention than ads on social media. Nearly two thirds of India’s streamers (64%) are more responsive to advertising on streaming platforms, with many stating they often search for the product (48%) and make a purchase (33%) after the fact. The study also found that free or ad-supported content is preferred to paying for an ad-free experience. 80% of streamers prefer to watch ad-supported content versus subscribing to an ad-free platform for a monthly fee. “OTT...

Proactive news headlines including QMines Ltd, OzAurum Resources, Narryer Metals and Green Technology Metals

Written by Customer Service on November 22, 2022. Posted in Mergers And Acquisitions.

Sydney, Nov. 22, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:QMines Ltd (ASX:QML) has delivered a 104% increase in resource tonnage to 11.86 million tonnes at 1.22% copper equivalent at the flagship Mt Chalmers Project in Queensland with 84% in the measured and indicated categories. Click here OzAurum Resources Ltd (ASX:OZM) welcomes high-grade gold results from diamond drill holes recently completed at the company’s flagship Mulgabbie North Project in the Eastern Goldfields of Western Australia. Click here Narryer Metals Ltd (ASX:NYM) has hit a new record high after returning high-grade rare earth elements (REE) and scandium results in re-assays of pulp samples from previous reverse circulation (RC) drilling at...

Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

Written by Customer Service on November 22, 2022. Posted in Public Companies.

Bagsværd, Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply our global clinical trials. These expansions will provide capacity for developing Novo Nordisk’s future oral and injectable product portfolio. “This investment in expanding our clinical API capacity in Bagsværd is an important step to ensure the continuous progress of our development pipeline. Increasing our API capacity in R&D will be a key enabler in bringing new innovations to the market, and meet the future demand of our patients”, said Jesper...

Alkaline Fuel Cell Power Corp. Announces Letter of Intent for Joint Venture with AmmPower Corp. for Fuel Cell Generator Pilot Using Green Ammonia

Written by Customer Service on November 22, 2022. Posted in Public Companies.

Image 1 AMMPOWER + PWWR OFF-GRID/BACKUP POWER GENERATORTORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) — Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (“PWWR” or the “Company”), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that on November 3rd, 2022, the Company executed a non-binding letter of intent (the “LOI”) with AmmPower Corp. (“AmmPower”), a company developing technology to convert green ammonia into green hydrogen. The LOI summarizes the intentions of the Company and AmmPower entering into a joint venture (the ”JV”) for the development of a pilot project testing PWWR’s off-grid fuel cell generator and AmmPower’s ammonia cracking technology (the “Pilot”). “Given North America is years away from being...

Semantix Announces Date of Third Quarter 2022 Financial Results

Written by Customer Service on November 22, 2022. Posted in Public Companies.

SÃO PAULO, Brazil, Nov. 21, 2022 (GLOBE NEWSWIRE) — Semantix, Inc. (NASDAQ: STIX), Latin America’s first fully integrated data platform, today announced it will release its financial results for the third quarter of 2022, which ended on September 30, 2022, following the close of the U.S. markets on Tuesday, November 29th, 2022. On Wednesday, November 30th, 2022, Semantix will host a conference call to discuss its financial results. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time on November 30th, 2022 and will be webcast live on Semantix`s Investor Relations website at ir.semantix.ai/news-events/events. Parties interested in participating via telephone may register using this online form. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number...

Day: November 22, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice